- Home
- ALKS
ALKS
Alkermes plc
as 11-20-2024 4:00pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 4.8B | IPO Year: | 1991 |
| Target Price: | $35.42 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.97 | EPS Growth: | 55.25 |
| 52 Week Low/High: | $22.22 - $32.88 | Next Earning Date: | 10-24-2024 |
| Revenue: | $1,505,121,000 | Revenue Growth: | -5.37% |
| Revenue Growth (this year): | -7.48% | Revenue Growth (next year): | -5.78% |
Latest Alkermes plc News
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Alkermes Insider Sold Shares Worth $1,774,576, According to a Recent SEC Filing
PR Newswire
10 days ago
Alkermes to Participate in Two Upcoming Investor Conferences
PR Newswire
14 days ago
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
MT Newswires
16 days ago
Stifel Upgrades Alkermes to Buy From Hold, Adjusts Price Target to $36 From $25
Zacks
a month ago
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Simply Wall St.
a month ago
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations
GuruFocus.com
a month ago
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ...
Zacks
a month ago
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Compare ALKS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.